Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. - Long, Georgina V; Saw, Robyn P M; Lo, Serigne; Nieweg, Omgo E; Shannon, Kerwin F; Gonzalez, Maria; Guminski, Alexander; Lee, Jenny H; Lee, Hansol; Ferguson, Peter M; Rawson, Robert V; Wilmott, James S; et al. (Lancet Oncology, 2019)